Neutropenia Treatment Market Size, Share, Trends and Forecast 2034
Global Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, Drug Type, By Route of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jun-2025 | Report ID: PHAR2510 | Pages: 1 - 284 | Formats*: |
| Category : Pharmaceutical | |||
Neutropenia Treatment Market Introduction and Overview
According to SPER Market Research, the Global Neutropenia Treatment Market is estimated to reach USD 23.12 billion by 2034 with a CAGR of 4.33%.
The report includes an in-depth analysis of the Global Neutropenia Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The market for neutropenia therapy, which was valued at USD 15.13 billion in 2024, is expected to expand at a compound annual growth rate (CAGR) of around 4.33% between 2025 and 2034. This growth is being driven by the rising incidence of neutropenia, which is characterised by unusually low neutrophil numbers, which has increased the need for treatment. Furthermore, the growing prevalence of conditions including cancer and autoimmune diseases, which can result in neutropenia, increased demand for efficient treatments and propelled market expansion.
By Treatment Type Insights:
The global neutropenia treatment industry is divided into categories based on treatment type, including colony-stimulating factors (CSFs), antibiotics, antifungals, antivirals, and other treatments. In 2024, the CSF category led the market, owing mostly to granulocyte colony-stimulating factor (G-CSF), which stimulates the production of neutrophils, which are essential for fighting infections. Neutropenia can occur when neutrophil levels drop, often due to chemotherapy. G-CSF helps increase white blood cell counts in the bone marrow, reducing infection risks for patients undergoing treatments that weaken their immune systems.
By Drug Type Insights:
The market is also categorized by drug type into branded drugs and biosimilars. Branded neutropenia drugs are expected to hold the largest market share in 2024, thanks to their established efficacy and recognition among healthcare providers and patients. Biosimilars, while offering similar effects and safety at lower costs, are anticipated to grow due to factors like patent expirations and regulatory support.
By Route of Administration Insights:
The market is divided into two routes of administration: oral and parenteral. In 2024, the parenteral route was the most popular choice. This method delivers treatments directly under the skin or into the bloodstream, skipping the digestive system. Its advantages include quick action, accurate dosing, and high bioavailability. For treating neutropenia, parenteral administration allows timely medication delivery, improving management of neutrophil levels and lowering infection risks, thus boosting segment growth.
Regional Insights:
North America is expected to have a considerable market share due to factors such as rising cancer incidence, desire for disease-specific treatment, strong healthcare spending, well-established infrastructure, and the presence of prominent industry participants. Furthermore, firms' increased attention on creating sophisticated and effective medicines for neutropenia treatment, together with rising drug approvals, adds significantly to market expansion.
Market Competitive Landscape:
The neutropenia treatment sector is characterised by high competition among significant players who strive to innovate and create effective medicines to meet the demands of neutropenic patients. Major pharmaceutical and biotechnology businesses are focussing on key tactics such as product innovation, strategic collaborations, mergers and acquisitions, and regional expansions to obtain a competitive advantage.
Recent Developments:
In December 2023, Coherus BioSciences, Inc. got FDA approval for its on-body injector version of the biosimilar pegfilgrastim-cbqv, called Udencya Onbody. This device helps cancer patients after chemotherapy to lower the risk of febrile neutropenia.
In November 2023, Evive Biotech and Acrotech Biopharma received FDA approval for Ryzneuta, designed to reduce infection rates in adults with certain cancers during anti-cancer treatment.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Treatment Type, By Drug Type, By Route of Administration, By Indication, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, CuraTeQ Biologics Pvt. Ltd, Evive Biotech, Kyowa Kirin Co., Ltd, Pfizer Inc, Sandoz Inc. |
- Global Neutropenia Treatment Market Size (FY 2021-FY 2034)
- Overview of Global Neutropenia Treatment Market
- Segmentation of Global Neutropenia Treatment Market By Treatment Type (CSF, Antibiotics, Antifungal, Antiviral)
- Segmentation of Global Neutropenia Treatment Market By Drug Type (Branded, Biosimilar)
- Segmentation of Global Neutropenia Treatment Market By Route of Administration (Oral, Parenteral)
- Segmentation of Global Neutropenia Treatment Market By Indication (Chemotherapy-induced neutropenia, Cyclic neutropenia, Idiopathic neutropenia, Congenital neutropenia)
- Segmentation of Global Neutropenia Treatment Market By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies)
- Statistical Snap of Global Neutropenia Treatment Market
- Expansion Analysis of Global Neutropenia Treatment Market
- Problems and Obstacles in Global Neutropenia Treatment Market
- Competitive Landscape in the Global Neutropenia Treatment Market
- Details on Current Investment in Global Neutropenia Treatment Market
- Competitive Analysis of Global Neutropenia Treatment Market
- Prominent Players in the Global Neutropenia Treatment Market
- SWOT Analysis of Global Neutropenia Treatment Market
- Global Neutropenia Treatment Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4.Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Neutropenia Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Neutropenia Treatment Market
7. Global Neutropenia Treatment Market, By Treatment Type (USD Million) 2021-2034
- 7.1. Colony-stimulating factors (CSFs)
- 7.2. Antibiotics
- 7.3. Antifungals
- 7.4. Antivirals
- 7.5. Other treatment types
8. Global Neutropenia Treatment Market, By Drug Type (USD Million) 2021-2034
- 8.1. Branded
- 8.2. Biosimilars
9. Global Neutropenia Treatment Market, By Route of Administration (USD Million) 2021-2034
- 9.1. Oral
- 9.2. Parenteral
10. Global Neutropenia Treatment Market, By Indication (USD Million) 2021-2034
- 10.1. Chemotherapy-induced neutropenia
- 10.2. Cyclic neutropenia
- 10.3. Idiopathic neutropenia
- 10.4. Congenital neutropenia
11. Global Neutropenia Treatment Market, By Distribution Channel (USD Million) 2021-2034
- 11.1. Hospital pharmacies
- 11.2. Retail pharmacies
- 11.3. Online pharmacies
12. Global Neutropenia Treatment Market, (USD Million) 2021-2034
- 12.1. Global Neutropenia Treatment Market Size and Market Share
13. Global Neutropenia Treatment Market, By Region, (USD Million) 2021-2034
- 13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
- 13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
- 13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
- 13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
- 13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America
14. Company Profile
- 14.1. Amgen Inc
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
- 14.2. BeyondSpring Inc
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
- 14.3. Biocon Biologics Inc
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
- 14.4. Cellerant Therapeutics
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
- 14.5. Coherus BioSciences, Inc
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
- 14.6. CuraTeQ Biologics Pvt. Ltd
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
- 14.7. Evive Biotech
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
- 14.8. Kyowa Kirin Co., Ltd
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
- 14.9. Pfizer Inc
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
- 14.10. Sandoz Inc
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Product summary
- 14.10.4. Recent developments
- 14.11. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Neutropenia Treatment Market is projected to reach USD 23.12 billion by 2034, growing at a CAGR of of 4.33% during the forecast period.
Neutropenia Treatment Market grew in Market size from 2025. The Market is expected to reach USD 23.12 billion by 2034, at a CAGR of 4.33% during the forecast period.
Neutropenia Treatment Market CAGR of 4.33% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Neutropenia Treatment Market size is USD 23.12 billion from 2025 to 2034.
Neutropenia Treatment Market is covered By Treatment Type, By Drug Type, By Route of Administration, By Indication, By Distribution Channel
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Neutropenia Treatment Market .
Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, CuraTeQ Biologics Pvt. Ltd, Evive Biotech, Kyowa Kirin Co., Ltd, Pfizer Inc, Sandoz Inc.
The report includes an in-depth analysis of the Global Neutropenia Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
